CAMBRIDGE COGNITION HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52 GBX | 0.00% |
|
0.00% | +0.97% |
| 04-23 | Cambridge Cognition partly-owned spin-off gets GBP1.5 million funding | AN |
| 04-23 | Cambridge Cognition's Spin-Out Company Closes Fundraise for Schizophrenia Drug | MT |
| Sales 2023 * | 13.5M 16.86M 1.35B | Sales 2024 * | 16M 19.99M 1.6B | Capitalization | 16.17M 20.2M 1.62B |
|---|---|---|---|---|---|
| Net income 2023 * | -3M -3.75M -300M | Net income 2024 * | - 0 0 | EV / Sales 2023 * | 1.18 x |
| Net cash position 2023 * | 200K 250K 20M | Net cash position 2024 * | 150K 187K 15M | EV / Sales 2024 * | 1 x |
| P/E ratio 2023 * |
-5.15
x | P/E ratio 2024 * |
-37.4
x | Employees | 80 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 71.79% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -7.47% | ||
| 1 month | -5.45% | ||
| 3 months | +5.05% | ||
| 6 months | -27.78% | ||
| Current year | +0.97% |
1 week
51.51
53.00
1 month
50.0055.00
Current year
47.2360.00
1 year
47.23104.00
3 years
47.23195.00
5 years
16.50195.00
10 years
16.50195.00
| Managers | Title | Age | Since |
|---|---|---|---|
Matthew Stork
CEO | Chief Executive Officer | 55 | 11/03/19 |
Stephen Symonds
DFI | Director of Finance/CFO | 50 | 05/04/22 |
Steven Powell
CHM | Chairman | 63 | 05/07/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Bungay
BRD | Director/Board Member | 55 | 13/09/20 |
Stuart Gall
BRD | Director/Board Member | 62 | 01-31 |
Steven Powell
CHM | Chairman | 63 | 05/07/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 52 | 0.00% | 4,800 |
| 25/04/24 | 52 | 0.00% | 3,759 |
| 24/04/24 | 52 | 0.00% | 30,351 |
| 23/04/24 | 52 | 0.00% | 49,034 |
| 22/04/24 | 52 | 0.00% | 0 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotes
Cambridge Cognition Holdings plc is a neuroscience technology company. The Company develops and markets digital solutions to assess brain health, principally in the United Kingdom, the United States and Europe. Its products include CANTAB Recruit, CANTAB Connect, Cognition Kit, Cognition eCOA, CANTAB Connect Research, CANTAB Mobile, CANTAB BrainHealth, CANTAB Insight, and NeuroVocalix. CANTAB Recruit is an online trial recruitment platform helping pharmaceutical and biotechnology companies identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease. CANTAB Connect offers digital cognitive assessment solutions for pharmaceutical clinical trials in therapeutic areas from phases I - IV. Cognition Kit is a custom-designed digital health platform delivering wearable and smartphone apps for high frequency data collection. It serves specialist contract research organizations, academic research institutions, and international healthcare providers.
Sector
Software
Calendar
18/09/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.52
GBP
Average target price
2.075
GBP
Spread / Average Target
+299.04%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.97% | 20.14M | |
| -20.09% | 26.53B | |
| +1.38% | 9.32B | |
| -6.43% | 4.6B | |
| -25.68% | 729M | |
| -1.92% | 479M | |
| -9.71% | 448M | |
| -9.63% | 273M | |
| -28.88% | 210M | |
| -42.63% | 189M |
- Stock Market
- Equities
- COG Stock
